People: Biogen Idec Inc (BIIB.O)

BIIB.O on Nasdaq

303.55USD
21 Nov 2014
Price Change (% chg)

$4.45 (+1.49%)
Prev Close
$299.10
Open
$305.28
Day's High
$305.28
Day's Low
$301.32
Volume
1,828,008
Avg. Vol
1,349,547
52-wk High
$358.89
52-wk Low
$245.31

Search Stocks

Rowinsky, Eric 

Brief Biography

Dr. Eric K. Rowinsky, M.D., is Independent Director of Biogen Idec Inc., since March 2010. Dr. Rowinsky has been the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells, since January 2012. Dr. Rowinsky is also an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. Dr. Rowinsky is a member of the boards of directors of Coronado Biosciences, Inc. and Navidea Biopharmaceuticals, Inc., both life sciences companies. During the past five years, Dr. Rowinsky has also served as a director of Mast Therapeutics, Inc. (formerly Adventrx Pharmaceuticals, Inc.) and Tapestry Pharmaceuticals, Inc., both life sciences companies.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Stelios Papadopoulos

--

George Scangos

15,015,100

Paul Clancy

4,486,260

Kenneth Di Pietro

3,254,520

Susan Alexander

2,162,200

John Cox

3,671,600
As Of 30 Dec 2013
Search Stocks